Lucid Diagnostics (LUCD) risk factors, FY2025 10-K

Lucid Diagnostics's FY2025 10-K, filed Mar 25, 2026, lists 66 risk factors. Against the prior year's 65: 11 new, 10 dropped, 35 substantially reworded.

Open LUCD in Gloom →
Lucid Diagnostics' chart, financials and news, free in your browser.Open LUCD in Gloom →
Risk factors listed
660 groups
New this year
11vs 65 last year
Dropped
10since the prior 10-K
Substantially reworded
35of those kept
Section length
25k wordsItem 1A

What the changes say

  • Lucid Diagnostics relies heavily on commercializing its EsoGuard test and EsoCheck device, facing going concern doubts and the need for capital.

What changed since the prior 10-K

New

  • New

    If private or governmental third-party payors do not maintain reimbursement for our products at adequate reimbursement rates, we may be unable to successfully commercialize our products which would limit or slow our revenue generation and likely have a material adverse effect on our business

    If third-party payors do not maintain adequate reimbursement rates, or if we fail to maintain CLIA certification or properly market EsoGuard and EsoCheck as a combined IVD device without FDA approval, our commercialization could be limited or halted.

  • New

    We are subject to all of the risks and uncertainties typically faced by a medical device and diagnostic company devoting substantially all its efforts to the commercialization of its initial products and services and ongoing research and development activities and clinical trials

    We have concluded there is substantial doubt about our ability to continue as a going concern due to recurring operating losses and cash flows, requiring us to raise additional capital beyond March 2027.

  • New

    may adversely affect prevailing market prices for our common stock

    Incurring indebtedness could result in defaults, asset foreclosures, acceleration of repayment, or covenants restricting our financing and business activities.

  • New

    the extent to which we acquire or invest in businesses, products and technologies, although we currently have no commitments or agreements relating to any of these types of transactions

    PAVmed may require cash payments under our management services agreement to fund its own operations, which increases our need to raise additional capital and could dilute existing stockholders.

  • New

    Our products may never achieve market acceptance, despite our investment of significant time and resources to drive adoption

    Our products may never achieve market acceptance due to factors like physician adoption rates, pricing, effectiveness, and medical society screening guidelines.

  • New

    in the case of FDA PMA approval of the EsoGuard combined with EsoCheck as an IVD device, and in the case of any other products or services we may develop in the future, the timing of regulatory approvals of our products and market entry compared to competitive products

    Convincing physicians, payors, or health systems to adopt our products involves a lengthy sales cycle of 12-18 months or longer, and our total addressable market estimates may be inaccurate.

  • New

    state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers

    We are subject to the Federal Anti-Kickback Statute, the Physician Payments Sunshine Act, the False Claims Act, EKRA, and state law equivalents, which impose strict penalties for healthcare fraud and improper referral inducements.

  • New

    failure by patients or physicians to provide complete and correct billing information

    Failure by patients or physicians to provide correct billing information, or un-contracted payors denying coverage without permission to bill patients, could adversely impact our business.

  • New

    the availability of capital

    Changes in regulatory requirements may force us to amend clinical study protocols, resubmit to institutional review boards, or face increased scrutiny and potential device recalls or distribution restrictions.

  • New

    the protection of computing systems maintaining electronic PHI

    We must comply with HIPAA privacy, security, and breach notification regulations, as well as state and foreign laws, risking significant fines for wrongful use or disclosure of protected health information.

  • New

    Any of the foregoing could affect our ability to compete or have a material adverse effect on our financial condition and results of operations

    Competitors may violate our intellectual property rights, forcing us to engage in expensive litigation that could divert management attention from our business strategy.

Dropped

  • Dropped

    Risks Associated with Our Financial Condition

    Operating losses and going concern doubts.

  • Dropped

    Risks Associated with Our Business

    Limited operating history and competitive technologies.

  • Dropped

    Risks Associated with Our Intellectual Property and Technology Infrastructure

  • Dropped

    Risks Associated with Our Relationship with PAVmed

    Intellectual property protection and infringement claims.

  • Dropped

    Risks Associated with Ownership of Our Common Stock

    PAVmed voting stock influence and convertible debt control.

  • Dropped

    Despite our initiative to establish a robust cash-pay program, successful commercialization of our EsoGuard test and EsoCheck device, and of any other product or service we develop, license or acquire depends, in large part, on the availability of adequate reimbursement from private or governmental third-party payors

    Analyst coverage, Nasdaq delisting, and stock price volatility.

  • Dropped

    Category of IVD Stage 1 Stage 2 Stage 3 Stages 4 & 5 (Premarket Review)

  • Dropped

    EsoCheck and any other products we develop that receive regulatory clearance or approval will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements

  • Dropped

    We may be subject to intellectual property infringement claims by third parties which could be costly to defend, divert management’s attention and resources, and may result in liability

  • Dropped

    We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors

Reworded

  • 100% rewritten

    We have incurred operating losses since our inception and may not be able to achieve profitability

    The risk was updated to remove specific net loss figures of $45.5 million for 2024 and $52.7 million for 2023.

  • 100% rewritten

    Since we have a limited operating history, and have not generated any significant revenues to date, you will have little basis upon which to evaluate our ability to achieve our business objective

    The risk shifted from limited operating history to focusing on competitive threats, reliance on CWRU license agreement, and market acceptance.

  • 100% rewritten

    The sizes of the markets for our current and future products have not been established with precision, and may be smaller than we estimate

    The risk shifted from target addressable market estimation assumptions to the impact of published clinical practice guidelines on payor coverage and physician prescriptions.

  • 100% rewritten

    We or our third-party manufacturers may not have the manufacturing and processing capacity to meet the production requirements of consumer demand or clinical testing in a timely manner

    The risk shifted from general manufacturing capacity to facility space limitations for the EsoGuard test and risks of laboratory disruption.

  • 100% rewritten

    Our results of operations can be adversely affected by labor shortages, turnover, and labor cost increases

    The risk shifted from general labor shortages and remote work to reliance on courier delivery services for EsoCheck and EsoGuard kits.

  • 100% rewritten

    Our ability to be successful will be totally dependent upon the efforts of our key personnel

    The risk added officer and director fiduciary conflicts of interest, business management challenges, macroeconomic conditions, and unsuccessful acquisitions.

  • 100% rewritten

    The results of our clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects

    The risk expanded to include provider and payor skepticism regarding EsoGuard and EsoCheck reliability, plus ongoing regulatory obligations.

  • 100% rewritten

    Our medical products may in the future be subject to product recalls that could harm our reputation, business, and financial results

    The risk added medical device reporting regulations for deaths or serious injuries, product liability lawsuits, and HIPAA compliance costs.

  • 100% rewritten

    Competitors may violate the intellectual property rights for the technology used in, or expected to be used in, our products, and we may bring litigation to protect and enforce our intellectual property rights, which may result in substantial expense and may divert our attention from implementing our business strategy

  • 100% rewritten

    PAVmed holds more voting stock than any of our other shareholders and thus it (or any successor to its stake in the Company), may have significant influence over certain actions requiring a stockholder vote

  • 100% rewritten

    We incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives

  • 100% rewritten

    promote market acceptance of our products

    Was: Our products may never achieve market acceptance

  • 95% rewritten

    Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management

  • 95% rewritten

    We have concluded there is substantial doubt of our ability to continue as a going concern and our independent registered public accounting firm’s report on our financial statements contains an explanatory paragraph describing our ability to continue as a going concern

  • 94% rewritten

    Modifications to our cleared or approved products may require new clearances or premarket approvals, or may require us to cease marketing or recall the modified products until clearances are obtained

  • 94% rewritten

    Certain conflicts of interest may arise between us and our affiliated companies, including PAVmed, and in some cases we have waived certain rights with respect thereto

  • 94% rewritten

    Our principal ongoing clinical trials are those that relate to EsoGuard. For a summary of the status and certain information concerning the results of those trials, please see above under “Background and Overview—Clinical Utility and Clinical Trials”

  • 93% rewritten

    We are subject to evolving corporate governance and public disclosure expectations and regulations that impact compliance costs and risks of noncompliance

  • 92% rewritten

    Risks Associated with Healthcare Regulation, Billing and Reimbursement, and Product Safety and Effectiveness

  • 90% rewritten

    If we are found to be promoting the use of our devices for unapproved or “off-label” uses or engaging in other noncompliant activities, we may be subject to recalls, seizures, fines, penalties, injunctions, adverse publicity, prosecution, or other adverse actions, resulting in damage to our reputation and business

  • 89% rewritten

    As a result of the exercise by the holder of PAVmed’s debt of its rights under the agreements governing that instrument, such holder could acquire voting control of the Company

    Was: As a result of the exercise by the holder of PAVmed’s convertible debt and preferred stock of its rights under the agreements governing those instruments, such holder could acquire voting control of the Company

  • 87% rewritten

    We also rely on the use of registered and common law trademarks with respect to the brand names of some of our products. Common law trademarks provide less protection than registered trademarks

  • 87% rewritten

    Our quarterly operating results could be subject to significant fluctuation, which could increase the volatility of our stock price and cause losses to our stockholders

  • 86% rewritten

    Failure to obtain regulatory approvals in foreign jurisdictions will prevent us from marketing our products internationally

  • 84% rewritten

    Recommendations in published clinical practice guidelines issued by various organizations, including professional societies and federal agencies may significantly affect payors’ willingness to cover, and physicians’ willingness to prescribe, our products and services

  • 81% rewritten

    We are obligated to pay dividends in shares of our common stock to the holders of shares of our Series B-1 Preferred Stock, which stock dividend will dilute our existing shareholders

    Was: We are obligated to pay dividends in shares of our common stock to the holders of shares of our Series B Preferred Stock and Series B-1 Preferred Stock, which stock dividends will dilute our existing shareholders

  • 80% rewritten

    We expect to need additional capital funding, which may be compounded by our obligations to our parent company, PAVmed, which requires its own additional capital funding

  • 76% rewritten

    Healthcare reform measures, including those targeting Medicare or Medicaid, could hinder or prevent our products’ commercial success

  • 67% rewritten

    Compliance with the HIPAA security, privacy and breach notification regulations may increase our costs

  • 59% rewritten

    Our internal computer systems, or those used by our third-party research institution collaborators, vendors or other contractors or consultants, may suffer security breaches

  • 43% rewritten

    Due to billing complexities in the diagnostic and laboratory service industry, we may not be able to collect payment for the EsoGuard tests we perform

  • 35% rewritten

    The manufacturing processes for our products have not yet been tested at large-scale commercial levels, and it may not be possible to manufacture or process these materials in a cost-effective manner

    Was: The manufacturing processes for our products have not yet been tested at commercial levels, and it may not be possible to manufacture or process these materials in a cost-effective manner

  • 34% rewritten

    Adverse results in material litigation matters could have a material adverse effect upon our business

  • 30% rewritten

    Additionally, the operations of our vendors and partners could also suffer from labor shortages, turnover, and labor cost increases which could result in supply chain disruptions and increases in the costs of the products and services we purchase, each of which could adversely affect our operations

  • 21% rewritten

    The debt service requirements of any other permitted indebtedness we incur or issue in the future, as well as the restrictive covenants contained in the governing documents for any such indebtedness, could intensify these risks

All 66 risk factors

Headings as the filing states them, in filing order.

Other

  1. 01We have incurred operating losses since our inception and may not be able to achieve profitability100% rewritten
  2. 02We have concluded there is substantial doubt of our ability to continue as a going concern and our independent registered public accounting firm’s report on our financial statements contains an explanatory paragraph describing our ability to continue as a going concern95% rewritten
  3. 03Our quarterly operating results could be subject to significant fluctuation, which could increase the volatility of our stock price and cause losses to our stockholders87% rewritten
  4. 04Since we have a limited operating history, and have not generated any significant revenues to date, you will have little basis upon which to evaluate our ability to achieve our business objective100% rewritten
  5. 05The sizes of the markets for our current and future products have not been established with precision, and may be smaller than we estimate100% rewritten
  6. 06We or our third-party manufacturers may not have the manufacturing and processing capacity to meet the production requirements of consumer demand or clinical testing in a timely manner100% rewritten
  7. 07Our results of operations can be adversely affected by labor shortages, turnover, and labor cost increases100% rewritten
  8. 08Our ability to be successful will be totally dependent upon the efforts of our key personnel100% rewritten
  9. 09If private or governmental third-party payors do not maintain reimbursement for our products at adequate reimbursement rates, we may be unable to successfully commercialize our products which would limit or slow our revenue generation and likely have a material adverse effect on our businessNew
  10. 10Modifications to our cleared or approved products may require new clearances or premarket approvals, or may require us to cease marketing or recall the modified products until clearances are obtained94% rewritten
  11. 11The results of our clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects100% rewritten
  12. 12If we are found to be promoting the use of our devices for unapproved or “off-label” uses or engaging in other noncompliant activities, we may be subject to recalls, seizures, fines, penalties, injunctions, adverse publicity, prosecution, or other adverse actions, resulting in damage to our reputation and business90% rewritten
  13. 13Our medical products may in the future be subject to product recalls that could harm our reputation, business, and financial results100% rewritten
  14. 14Competitors may violate the intellectual property rights for the technology used in, or expected to be used in, our products, and we may bring litigation to protect and enforce our intellectual property rights, which may result in substantial expense and may divert our attention from implementing our business strategy100% rewritten
  15. 15PAVmed holds more voting stock than any of our other shareholders and thus it (or any successor to its stake in the Company), may have significant influence over certain actions requiring a stockholder vote100% rewritten
  16. 16Certain conflicts of interest may arise between us and our affiliated companies, including PAVmed, and in some cases we have waived certain rights with respect thereto94% rewritten
  17. 17We incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives100% rewritten
  18. 18Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management95% rewritten
  19. 19We are subject to all of the risks and uncertainties typically faced by a medical device and diagnostic company devoting substantially all its efforts to the commercialization of its initial products and services and ongoing research and development activities and clinical trialsNew
  20. 20may adversely affect prevailing market prices for our common stockNew
  21. 21We expect to need additional capital funding, which may be compounded by our obligations to our parent company, PAVmed, which requires its own additional capital funding80% rewritten
  22. 22promote market acceptance of our products100% rewritten
  23. 23the extent to which we acquire or invest in businesses, products and technologies, although we currently have no commitments or agreements relating to any of these types of transactionsNew
  24. 24We may be required to repay or redeem at maturity in 2029 (or sooner, upon the occurrence of certain change of control transactions or an event of default), or to pay interest on, the 2024 Convertible Notes or any future permitted indebtedness incurred by us or our subsidiaries, in cash
  25. 25The debt service requirements of any other permitted indebtedness we incur or issue in the future, as well as the restrictive covenants contained in the governing documents for any such indebtedness, could intensify these risks21% rewritten
  26. 26The markets in which we operate are attractive and other companies or institutions may develop and market novel or improved technologies, which may make the EsoGuard or EsoCheck technologies less competitive or obsolete
  27. 27We expect to derive substantially all of our revenues from the EsoGuard and EsoCheck products
  28. 28We are highly dependent on our license agreement with CWRU, the termination of which would prevent us from commercializing our products, and which imposes significant obligations on us
  29. 29Our products may never achieve market acceptance, despite our investment of significant time and resources to drive adoptionNew
  30. 30in the case of FDA PMA approval of the EsoGuard combined with EsoCheck as an IVD device, and in the case of any other products or services we may develop in the future, the timing of regulatory approvals of our products and market entry compared to competitive productsNew
  31. 31Recommendations in published clinical practice guidelines issued by various organizations, including professional societies and federal agencies may significantly affect payors’ willingness to cover, and physicians’ willingness to prescribe, our products and services84% rewritten
  32. 32The manufacturing processes for our products have not yet been tested at large-scale commercial levels, and it may not be possible to manufacture or process these materials in a cost-effective manner35% rewritten
  33. 33Additionally, the operations of our vendors and partners could also suffer from labor shortages, turnover, and labor cost increases which could result in supply chain disruptions and increases in the costs of the products and services we purchase, each of which could adversely affect our operations30% rewritten
  34. 34Our officers and directors have fiduciary obligations to other companies and, accordingly, may have conflicts of interest in determining to which entity a particular business opportunity should be presented
  35. 35Our business may suffer if we are unable to manage our growth
  36. 36Our business, financial condition and results of operations could be adversely affected by the political and economic conditions of the U.S. and the other countries in which we conduct business
  37. 37We may engage in acquisitions that are not successful and which could disrupt our business, cause dilution to our stockholders and reduce our financial resources
  38. 38Adverse results in material litigation matters could have a material adverse effect upon our business34% rewritten
  39. 39Risks Associated with Healthcare Regulation, Billing and Reimbursement, and Product Safety and Effectiveness92% rewritten
  40. 40Securing FDA approval of EsoGuard as an IVD device, separately or as a combined product with EsoCheck, is a complex process requiring substantial time, commitment of resources and expense without any assurance that FDA will grant such approval
  41. 41Failure to obtain regulatory approvals in foreign jurisdictions will prevent us from marketing our products internationally86% rewritten
  42. 42Our principal ongoing clinical trials are those that relate to EsoGuard. For a summary of the status and certain information concerning the results of those trials, please see above under “Background and Overview—Clinical Utility and Clinical Trials”94% rewritten
  43. 43state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurersNew
  44. 44The regulations that govern pricing and reimbursement for new products vary widely from country to country, and may adversely affect the pricing, coverage and reimbursement rates of our products in other countries
  45. 45Due to billing complexities in the diagnostic and laboratory service industry, we may not be able to collect payment for the EsoGuard tests we perform43% rewritten
  46. 46failure by patients or physicians to provide complete and correct billing informationNew
  47. 47Healthcare reform measures, including those targeting Medicare or Medicaid, could hinder or prevent our products’ commercial success76% rewritten
  48. 48the availability of capitalNew
  49. 49If our medical products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions
  50. 50Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of our products
  51. 51Compliance with the HIPAA security, privacy and breach notification regulations may increase our costs67% rewritten
  52. 52the protection of computing systems maintaining electronic PHINew
  53. 53We may not be able to protect or enforce the intellectual property rights for the technology used in, or expected to be used in, our products, which could impair our competitive position
  54. 54We also rely on the use of registered and common law trademarks with respect to the brand names of some of our products. Common law trademarks provide less protection than registered trademarks87% rewritten
  55. 55Any of the foregoing could affect our ability to compete or have a material adverse effect on our financial condition and results of operationsNew
  56. 56Failure in our information technology systems could significantly disrupt our operations and our research and development efforts, which could adversely impact our revenues, as well as our research, development and commercialization efforts
  57. 57Our internal computer systems, or those used by our third-party research institution collaborators, vendors or other contractors or consultants, may suffer security breaches59% rewritten
  58. 58As a result of the exercise by the holder of PAVmed’s debt of its rights under the agreements governing that instrument, such holder could acquire voting control of the Company89% rewritten
  59. 59Any disputes that arise between us and PAVmed with respect to our past and ongoing relationships could harm our business operations
  60. 60If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline
  61. 61Nasdaq may in the future delist our common stock, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions
  62. 62Our stock price may be volatile, and holders of our common stock could incur substantial losses
  63. 63We do not intend to pay any dividends on our common stock at this time
  64. 64We are obligated to pay dividends in shares of our common stock to the holders of shares of our Series B-1 Preferred Stock, which stock dividend will dilute our existing shareholders81% rewritten
  65. 65If we fail to establish and maintain proper and effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline significantly
  66. 66We are subject to evolving corporate governance and public disclosure expectations and regulations that impact compliance costs and risks of noncompliance93% rewritten

Other Lucid Diagnostics 10-Ks

  • FY2024 10-K risk factors
    65 risks

    Lucid Diagnostics relies heavily on commercializing its lead EsoGuard and EsoCheck products for esophageal precancer testing.

    Filed Mar 24, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.